Aflac
AFL
$115.18
-0.99%
Aflac Inc. is a supplemental health and life insurance provider operating primarily in the United States and Japan, offering cancer, accident, dental, vision, disability, and long-term-care policies sold largely through worksite distribution and digital channels. The company is a dominant niche player in supplemental insurance, with Aflac Japan representing its largest revenue segment and Aflac U.S. serving as the second pillar, giving it a distinct dual-market footprint that few U.S. insurers possess. The current investor narrative centers on Aflac's AI-driven operational efficiency push, its disciplined capital return program highlighted by an effective 8.3% shareholder yield through dividends and buybacks, and a sharp earnings recovery in 2026 following a volatile 2024-2025 period marked by a quarterly loss. Debate among investors focuses on whether the recent earnings rebound is sustainable given soft revenue growth, a low beta defensive profile, and persistent analyst skepticism reflected in multiple Underperform and Underweight ratings.…
AFL
Aflac
$115.18
Related headlines
Investment Opinion: Should I buy AFL Today?
The synthesized recommendation is Hold. Aflac's core thesis is a high-quality, low-beta defensive insurer with an 8.3% effective shareholder yield and a recovering earnings profile, but the stock is fairly valued at best, with the analyst consensus average target of $118.53 implying only +1.9% upside from $116.33. The absence of strong Buy ratings and the presence of multiple Underperform/Underweight ratings reinforce a cautious stance.
The supporting evidence is mixed but leans toward fair valuation. On the positive side, Q1 2026 net income of $1.019 billion and EPS of $1.99 represent a dramatic recovery from $29 million and $0.05 a year earlier, with net margin at 23.62% and gross margin at 57.54%. Free cash flow of $2.934 billion comfortably funds the 2.05% dividend yield and buybacks, and the debt-to-equity of 0.285 is conservative. However, the trailing PE of 16.07x is near the high end of its historical range, and the forward PE of 15.43x implies only 4% earnings growth, which is modest for a stock trading at a premium to the 10x-14x typical of life insurers.
The biggest risks that could invalidate the Hold thesis are a reversion in net margins toward the mid-teens, a deterioration in Aflac Japan's operating environment, and multiple compression if earnings growth stalls. The rating would upgrade to Buy if the forward PE compressed below 13x while net margins held above 20%, or if revenue growth accelerated above 15% without relying on a weak prior-year base. It would downgrade to Sell if net margins fell below 15% for two consecutive quarters or if the stock broke below the 52-week low of $105.43 on rising volume. Overall, Aflac appears fairly valued relative to its own history and slightly expensive versus peers, offering limited capital appreciation potential but a solid income stream.
Sign up to view all
AFL 12-Month Price Forecast
Aflac presents a balanced risk/reward profile with a neutral stance. The company's dramatic earnings recovery, fortress balance sheet, and 8.3% shareholder yield are offset by a premium valuation near historical highs and a skeptical analyst consensus that sees only 1.9% upside to the average target. The low beta of 0.58 and contained max drawdown of -11.64% make it a defensive holding, but the 15.45% one-month price decline signals waning momentum. I would upgrade to bullish if net margins hold above 22% for two consecutive quarters and the forward PE compresses below 14x, and downgrade to bearish if net margins fall below 15% or the stock breaks below the 52-week low of $105.43.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Aflac's 12-month outlook, with a consensus price target around $118.53 and implied upside of +2.9% versus the current price.
Average Target
$118.53
0 analysts
Implied Upside
+2.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$99 - $138
Analyst target range
Aflac is covered by 15 analysts, and the consensus recommendation is notably cautious, with the institutional ratings data showing a preponderance of neutral-to-bearish stances: Evercore ISI and Mizuho at Underperform, Barclays at Underweight, and multiple firms including Keefe Bruyette & Woods, Jefferies, Wells Fargo, UBS, and Morgan Stanley at Market Perform, Hold, Equal Weight, or Neutral, with only Piper Sandler at Overweight. The average target price is $118.53, which implies approximately +1.9% upside from the current price of $116.33, indicating that the consensus views the stock as roughly fairly valued with limited near-term appreciation potential. The consensus leans neutral-to-bearish, and the lack of any strong Buy ratings from the covering firms suggests limited conviction in a bullish thesis. The target price range spans from a low of $99.00 to a high of $138.00, a spread of $39.00 or roughly 33% of the current price, which signals meaningful disagreement among analysts about the company's prospects. The high target of $138.00 implies roughly +18.6% upside and would likely require multiple expansion, accelerating earnings growth, or successful execution on AI-driven efficiency initiatives and capital return. The low target of $99.00 implies roughly -14.9% downside and likely prices in margin compression, competitive pressures in the U.S. supplemental market, or a deterioration in Japan's operating environment. The wide spread, combined with the absence of recent upgrades and the presence of several Underperform/Underweight ratings, suggests high uncertainty and weak institutional conviction. The estimated EPS range of $7.92 to $8.30 and revenue range of $17.10 billion to $17.73 billion for the forward period are relatively tight, indicating that while analysts disagree on valuation, they broadly agree on near-term financial performance. The recent rating actions show no upgrades, with the most recent changes being reiterations of existing cautious stances, which reinforces the view that Aflac is a hold-at-best story for most of the sell-side community.
Bulls vs Bears: AFL Investment Factors
The bull case rests on a dramatic earnings recovery, a fortress balance sheet, and an 8.3% effective shareholder yield, all supported by a low-beta defensive profile. The bear case centers on a skeptical analyst consensus with only +1.9% average upside, a valuation multiple near historical highs, and revenue growth that is flattered by a weak prior-year base. Currently, the bear evidence carries slightly more weight because the stock trades at 16.07x trailing earnings versus a 7x-10x historical norm, while the sell-side shows multiple Underperform ratings and no strong Buys. The single most important tension is whether the Q1 2026 margin recovery is durable or merely a rebound from a transitory collapse; if net margins hold above 20% for several quarters, the premium multiple is justified, but if they revert toward the mid-teens, the stock could face meaningful multiple compression.
Bullish
- Earnings recovery is dramatic and broad: Q1 2026 net income of $1.019 billion and EPS of $1.99 compare to near-breakeven net income of $29 million and EPS of $0.05 in Q1 2025, a roughly 35x EPS increase. Net margin recovered to 23.62% from 0.84% a year earlier, and gross margin expanded to 57.54% from 14.19%, indicating the prior-year collapse was largely transitory.
- Fortress balance sheet with ample liquidity: The current ratio is 12.39 and debt-to-equity is only 0.285, leaving Aflac with substantial financial flexibility. Cash at period end was $5.654 billion, and trailing twelve-month free cash flow of $2.934 billion comfortably covers the $304 million quarterly dividend and $1.0 billion buyback.
- Shareholder yield near 8.3% is compelling: Aflac returned $1.304 billion to shareholders in Q1 2026 alone through dividends and buybacks, funded entirely from internal cash generation. The 2.05% dividend yield is backed by a conservative 32.86% payout ratio, and the effective 8.3% total shareholder yield provides a strong total-return cushion.
- Low beta defensive profile with contained drawdown: A beta of 0.58 means Aflac is roughly 42% less volatile than the market, and its max drawdown of -11.64% over the period is modest. This makes it an attractive portfolio stabilizer, especially with the stock still 10.7% below its 52-week high of $130.22 and trading at $116.33.
Bearish
- Analyst consensus is skeptical with limited upside: Of 15 covering analysts, several carry Underperform or Underweight ratings (Evercore ISI, Mizuho, Barclays), and the average target price of $118.53 implies only +1.9% upside from $116.33. The absence of any strong Buy ratings signals weak institutional conviction in a sustained re-rating.
- Revenue growth is uneven and base-flattered: Q1 2026 revenue of $4.315 billion grew 24.96% year-over-year, but this was against an unusually weak Q1 2025 base of $3.453 billion. Sequential revenue declined from $4.896 billion in Q4 2025, and the multi-quarter trend shows volatility rather than a clear acceleration.
- Valuation multiple is near historical highs: The trailing PE of 16.07x is well above the 7x-10x range seen through most of 2024 and early 2025, and the price-to-book of 1.98x is near the upper end of its historical band. This leaves the stock vulnerable to multiple compression if earnings growth disappoints.
- Recent price momentum has turned sharply negative: The 1-month price change is -15.45%, a sharp reversal from the 6-month gain of +9.52%, and the stock has lagged SPY by 7.30% over the past year. The pullback from the July peak of $129.55 suggests waning momentum and potential further mean reversion.
AFL Technical Analysis
Aflac is in a broad but choppy uptrend, with the current price of $116.33 sitting roughly 89% of the way through its 52-week range of $105.43 to $130.22, and a 1-year price change of +7.71%. The stock has recovered from its 52-week low area but remains about 10.7% below its 52-week high of $130.22, suggesting the trend is constructive but not euphoric. This positioning implies moderate momentum rather than overextension, with the stock neither a falling knife nor a momentum chase at current levels. Recent momentum has turned negative: the 1-month change is -15.45%, a sharp deceleration from the 3-month change of +0.74% and the 6-month change of +9.52%, signaling a meaningful pullback from the July peak near $129.55. This divergence between the positive 1-year trend and the negative 1-month trend suggests a temporary correction or mean reversion rather than a full trend reversal, especially given the stock's low beta of 0.58, which implies the pullback is more likely idiosyncratic than market-driven. The relative strength versus SPY is -7.30% over 1 year and -0.81% over 1 month, confirming Aflac has lagged the broader market recently. Key technical support sits near the 52-week low of $105.43, with intermediate support around the $114-$115 area where the stock has recently stabilized, while resistance is defined by the 52-week high of $130.22 and the July swing high near $129.55. A breakout above $130 would signal renewed institutional accumulation and could open the door to new highs, whereas a breakdown below $105 would confirm a deeper downtrend and likely trigger further selling. The beta of 0.58 means Aflac is roughly 42% less volatile than the market, which matters for position sizing: investors can hold a larger notional position for the same risk budget, but the trade-off is muted upside participation in broad rallies. The max drawdown of -11.64% over the period is relatively contained, consistent with the stock's defensive characteristics.
Beta
0.58
0.58x market volatility
Max Drawdown
-11.6%
Largest decline past year
52-Week Range
$105-$130
Price range past year
Annual Return
+6.6%
Cumulative gain past year
| Period | AFL Return | S&P 500 |
|---|---|---|
| 1m | -0.8% | +1.0% |
| 3m | -3.0% | +5.4% |
| 6m | +7.4% | +17.8% |
| 1y | +6.6% | +16.5% |
| ytd | +4.5% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
AFL Fundamental Analysis
Aflac's revenue trajectory has been uneven but is showing a strong rebound in the most recent quarter, with Q1 2026 revenue of $4.315 billion representing 24.96% year-over-year growth versus Q1 2025's $3.453 billion. However, the multi-quarter trend reveals volatility: Q4 2025 revenue was $4.896 billion, Q3 2025 was $4.793 billion, Q2 2025 was $4.218 billion, and Q1 2025 was $3.453 billion, indicating that the Q1 2026 growth rate is flattered by an unusually weak prior-year base. Segment data shows Aflac Japan Member contributing $2.172 billion and Aflac U.S. Member contributing $1.779 billion, with Other Segments at $292 million, confirming Japan remains the largest revenue driver. The growth trend implies the investment case hinges on whether the U.S. segment can accelerate to offset Japan's maturity, and the recent quarter's strength provides some encouragement but not yet a definitive inflection. Profitability is robust: Q1 2026 net income was $1.019 billion with a net margin of 23.62%, and gross margin of 57.54%, while the trailing net margin stands at 20.91% and operating margin at 26.61%. Margins have been volatile across quarters, with Q4 2025 net margin at 28.17% and Q3 2025 at 34.20%, but the Q1 2026 figure represents a dramatic recovery from Q1 2025's near-breakeven 0.84% net margin and the Q3 2024 net loss of -$93 million. The gross margin of 57.54% in Q1 2026 is well above the 28.05% recorded in Q2 2025 and the 14.19% in Q1 2025, suggesting improving underwriting or investment results. For the insurance industry, a net margin above 20% is strong, and Aflac's profitability is consistent with a well-run supplemental insurer with disciplined pricing. The balance sheet is exceptionally liquid and conservatively levered: the current ratio is 12.39, debt-to-equity is just 0.285, and ROE is 12.36% with ROA at 3.13%. Free cash flow on a trailing twelve-month basis is $2.934 billion, and Q1 2026 free cash flow was $968 million, comfortably covering the $304 million in dividends paid and the $1.0 billion in stock repurchases during the quarter. The company returned $1.304 billion to shareholders in Q1 2026 alone, funded entirely from internal cash generation, with cash at period end of $5.654 billion. The FCF yield, while not explicitly provided, can be approximated from the $2.934 billion TTM FCF against a $58.4 billion market cap, implying roughly 5.0%, which is healthy for a large-cap insurer and supports the sustainability of the dividend and buyback program.
Quarterly Revenue
$4.3B
2026-03
Revenue YoY Growth
+25.0%
YoY Comparison
Gross Margin
57.5%
Latest Quarter
Free Cash Flow
$2.9B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is AFL Overvalued?
Because Aflac is profitable with trailing net income of approximately $3.6 billion, the PE ratio is the appropriate primary valuation metric. The trailing PE is 16.07x while the forward PE is 15.43x, a modest 4% compression that implies the market expects only slight earnings growth over the next twelve months. The narrow gap between trailing and forward PE suggests the market is not pricing in aggressive growth acceleration, which is consistent with Aflac's mature, low-beta profile and the analyst consensus EPS estimate of $8.13 for the forward period. The PEG ratio of -0.55 is negative and therefore not meaningful, reflecting the distortion from prior-period earnings volatility rather than a genuine valuation signal. Compared to the broader insurance sector, where life insurers typically trade in the 10x-14x PE range, Aflac's trailing PE of 16.07x represents a premium of roughly 15-60% depending on the peer set, though this premium is partially justified by its superior net margin of 20.91% and ROE of 12.36%. The price-to-book ratio of 1.98x and price-to-sales ratio of 3.35x are moderate for a large-cap insurer, while the EV/EBITDA of 10.97x and dividend yield of 2.05% round out a valuation profile that is neither cheap nor expensive. The payout ratio of 32.86% is conservative and leaves ample room for continued dividend growth and buybacks, supporting the premium multiple. Historically, Aflac's PE ratio has ranged widely: it was 13.78x in Q1 2026, 10.60x in Q4 2025, 9.04x in Q3 2025, and spiked to 522x in Q1 2025 due to the earnings collapse, with a more normal 7.52x in Q4 2024 and 7.16x in Q2 2024. The current trailing PE of 16.07x is near the high end of its recent historical band, well above the 7x-10x range seen through most of 2024 and early 2025, suggesting the market is pricing in optimistic expectations relative to the company's recent earnings history. This elevated multiple relative to its own history implies either that the market believes the earnings recovery is durable and deserves a re-rating, or that the stock is vulnerable to multiple compression if growth disappoints. The PB ratio of 1.98x is also near the upper end of its historical range of roughly 1.0x to 2.5x, reinforcing the view that Aflac is not a value opportunity at current levels but rather a fairly-to-fully valued defensive holding.
PE
16.1x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 5x~14x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.0x
Enterprise Value Multiple
Investment Risk Disclosure
Aflac's financial risks are relatively contained but not negligible. The debt-to-equity ratio of 0.285 and current ratio of 12.39 indicate a conservatively levered balance sheet with ample liquidity, and trailing free cash flow of $2.934 billion covers the $1.304 billion returned to shareholders in Q1 2026. However, earnings volatility is a genuine concern: the company posted a net loss of $93 million in Q3 2024 and near-breakeven net income of $29 million in Q1 2025, demonstrating that investment losses or reserve strengthening can sharply swing results. Revenue concentration in Aflac Japan ($2.172 billion of $4.315 billion in Q1 2026) exposes the company to yen fluctuations and Japanese demographic trends, while the 24.96% Q1 2026 revenue growth is flattered by an unusually weak prior-year base.
Market and competitive risks are elevated by the stock's premium valuation. At a trailing PE of 16.07x, Aflac trades well above the 7x-10x range seen through most of 2024 and early 2025, and its price-to-book of 1.98x is near the upper end of its historical band, leaving little room for disappointment. The beta of 0.58 means the stock is less sensitive to broad market swings, but it also means Aflac will likely underperform in strong rallies, as evidenced by its 7.30% relative underperformance versus SPY over the past year. Competitive pressures in the U.S. supplemental insurance market and potential regulatory changes in Japan's insurance sector could pressure pricing and margins. The recent news highlighting AI-driven efficiency is a double-edged sword: while it supports the bull case, it also raises execution risk if the initiatives fail to deliver cost savings.
In a worst-case scenario, a combination of margin normalization, yen weakness, and multiple compression could drive the stock toward its 52-week low of $105.43 or the analyst low target of $99.00. From the current price of $116.33, that represents a decline of approximately 9.4% to the 52-week low and 14.9% to the analyst low target. A more severe scenario, such as a return to the Q1 2025 earnings collapse, could push the stock below $100, implying a loss of roughly 14-15%. The max drawdown of -11.64% over the observed period provides a recent reference for downside risk, but a genuine earnings miss or a deterioration in Japan's operating environment could produce a larger drawdown, potentially exceeding 20% from current levels.
FAQ
The most severe risk is earnings volatility, as demonstrated by the Q3 2024 net loss of $93 million and Q1 2025 near-breakeven net income of $29 million, which could recur if investment losses or reserve strengthening occur. Second, valuation compression risk is elevated because the trailing PE of 16.07x is near historical highs, and a re-rating toward the 10x-12x range would imply a stock price near $98. Third, concentration risk in Aflac Japan, which generated $2.172 billion of $4.315 billion in Q1 2026 revenue, exposes the company to yen fluctuations and Japanese demographic headwinds. Fourth, competitive pressures in the U.S. supplemental insurance market could pressure pricing and new business margins, while the low beta of 0.58 means the stock will likely lag in strong bull markets.
The 12-month forecast has three scenarios. The base case (55% probability) targets $115-$122, assuming EPS of $8.13 and net margins in the low-20% range, with the stock trading around the average analyst target of $118.53. The bull case (25% probability) targets $130-$138, driven by durable margin expansion above 22%, U.S. revenue acceleration, and multiple expansion toward 17-18x forward earnings. The bear case (20% probability) targets $99-$105, assuming margin normalization toward the mid-teens, yen weakness, and multiple compression toward the 10x-12x historical range. The base case is most likely, with the key assumption being that net margins remain between 20% and 24% for the next four quarters.
AFL appears fairly valued to slightly overvalued relative to its own history and peers. The trailing PE of 16.07x is well above the 7x-10x range seen through most of 2024 and early 2025, and the price-to-book of 1.98x is near the upper end of its historical band. Compared to the broader life insurance sector, which typically trades at 10x-14x earnings, Aflac carries a premium that is only partially justified by its 20.91% net margin and 12.36% ROE. The forward PE of 15.43x implies the market expects only 4% earnings growth, suggesting limited optimism is priced in. The stock is not a value opportunity at current levels; it is a fairly valued defensive holding with a solid dividend.
From a risk/reward perspective, AFL is a moderate buy for income-focused investors but offers limited capital appreciation potential. The stock trades at $116.33 with an average analyst target of $118.53, implying only +1.9% upside, and the forward PE of 15.43x is above the 10x-14x typical of life insurers. The biggest downside risk is a reversion in net margins toward the mid-teens, which could push the stock toward the analyst low target of $99.00, a 14.9% decline. However, the 8.3% effective shareholder yield and low beta of 0.58 provide a strong income cushion and defensive characteristics. It is a good buy for conservative investors seeking yield and low volatility, but growth-oriented investors may find better opportunities elsewhere.
AFL is best suited for long-term investment, with a suggested minimum holding period of 2-3 years. The company is a mature, low-beta (0.58) insurer with a 2.05% dividend yield and a conservative 32.86% payout ratio, making it an income-oriented holding rather than a short-term trading vehicle. The recent 15.45% one-month price decline and the stock's 7.30% relative underperformance versus SPY over the past year suggest that short-term momentum is negative, and the low beta means it will not participate fully in market rallies. However, the 8.3% effective shareholder yield and fortress balance sheet provide a solid foundation for long-term total returns. Short-term traders may find better opportunities in higher-beta names, while long-term investors can collect the dividend and benefit from gradual earnings recovery.